Latest News

There are 22 Australian-based companies working on the development of gene and cell therapy, according to a new report from the US-based Alliance for Regenerative Medicine.

A new report suggests Australia could be lagging behind comparable countries when it comes to the reimbursement of gene-based and cell therapies.

CSL Behring has welcomed confirmation three new presentations of human C1 esterase inhibitor concentrate will be available under the national blood arrangements.

"Every moment that the government does nothing about the funding for PHARMAC, they have blood on their hands," said Camilla Cox.

The transparency discussion is undermined by the fixation on outcomes and the focus on publishing information that realistically adds almost nothing to the community's understanding of how medicines are funded in Australia. This fixation is compounded by a power imbalance that sees all the pressure on the industry when it comes to transparency while 'backroom' processes remain a mysterious locked box.

CSL has been named by Forbes Magazine as one of its 500 Best Employers for Diversity in the US, along with a group of other pharmaceutical and biotechnology companies.

AbbVie has welcomed the TGA approval of once-daily JAK1 inhibitor RINVOQ (upadacitinib) for the treatment of rheumatoid arthritis.

API CEO Richard Vincent says he believes the government will continue to support the current model of pharmaceutical distribution in the Seventh Community Pharmacy Agreement.

New leadership for Biogen with the appointment of Kylie Bromley as managing director to succeed Christopher Stemple.

The association has launched its annual 2020 CEO Industry Position Survey in which it asks sector leaders to contribute their views and policy priorities for the Australian life sciences sector.

A New Zealand couple have taken the fight for more funding for PHARMAC across the country by riding a tandem bicycle towing a coffin from Invercargill to Wellington.

The Danish company is one of a small number of global pharmaceutical companies amongst the 179 companies to be recognised for their efforts to reduce CO2-emissions and energy consumption.